Zydelig
What Zydelig is used for
Zydelig is indicated in combination with an anti-CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL): who have received at least one prior therapy, or as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies. Zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Zydelig
- Active substance
- idelalisib
- Disease area
- Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell
- Medicine group
- Antineoplastic agents;Other antineoplastic agents
- ATC code
- L01XX47
- Marketing authorisation holder
- Gilead Sciences Ireland UC
- Authorised in the EU since
- 2014
Official information
In the USA
Same active substance: Zydelig
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Zydelig used for?
Zydelig is indicated in combination with an anti-CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL): who have received at least one prior therapy, or as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies. Zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.
What is the active substance in Zydelig?
Zydelig contains idelalisib.
Who makes Zydelig?
The EU marketing authorisation holder is Gilead Sciences Ireland UC.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU